Zepbound and Sildenafil Interaction: What Patients and Prescribers Need to Know

Is there an interaction between Zepbound and sildenafil?

Neither label's drug interactions section names the other drug. Zepbound's section deals with two things: insulin and insulin secretagogues such as sulfonylureas, because of hypoglycemia risk, and oral medicines in general, because tirzepatide delays gastric emptying [2]. Sildenafil's section deals with nitrates, alpha-blockers, amlodipine, CYP3A4 inhibitors and alcohol [1].

What links the two drugs is blood pressure. Sildenafil has vasodilatory effects that lower supine blood pressure in healthy volunteers [1], and Zepbound's adverse reaction tables list hypotension and dizziness [2]. That overlap is a shared effect, not evidence that the combination causes problems.

What the Zepbound label records about blood pressure

In the pooled weight-management trials behind the label (958 patients on placebo; 630 on 5 mg; 948 on 10 mg; 941 on 15 mg), hypotension was reported in 1.6% of tirzepatide-treated patients versus 0.1% on placebo. It was more frequent in patients taking antihypertensive medicines, 2.2%, than in those who were not, 1.2% [2]. The label's adverse reaction table lists hypotension in 1%, 1% and 2% of patients on 5, 10 and 15 mg versus 0% on placebo, and dizziness in 4%, 5% and 4% versus 2% [2]. Heart rate rose a mean of 1 to 3 beats per minute [2].

Zepbound delays gastric emptying and may affect oral medicines that depend on threshold concentrations or have a narrow therapeutic index, such as warfarin; the label advises monitoring these medicines when they are used with Zepbound [2]. Sildenafil is not named in that section.

What the sildenafil label records about blood pressure

The Viagra label reports a mean maximum decrease in supine blood pressure of 8.4/5.5 mmHg in healthy volunteers given single 100 mg doses, with no dose relationship between 25 and 100 mg [1]. Two comparisons in the label show how much a second blood-pressure-lowering drug adds:

• With amlodipine 5 or 10 mg in hypertensive patients, sildenafil 100 mg produced an additional mean supine reduction of 8 mmHg systolic and 7 mmHg diastolic [1].
• With alpha-blockers, the effect is additive and symptomatic hypotension can occur; the label says patients should be stable on the alpha-blocker first and sildenafil started at 25 mg [1].

The label also advises caution when sildenafil is co-administered with alpha-blockers or antihypertensives because concomitant use may lead to hypotension [1].

Alcohol is worth separating out: in a drug interaction study, sildenafil 50 mg given with alcohol to a mean peak blood alcohol of 0.08% did not potentiate alcohol's hypotensive effect in healthy volunteers [1].

Does tirzepatide change sildenafil blood levels?

Neither label describes a metabolic interaction between the two. Sildenafil is cleared mainly by CYP3A4, with CYP2C9 a minor route, and its active N-desmethyl metabolite carries about 50% of the parent drug's PDE5 potency [1]. Strong inhibitors matter a great deal: ritonavir raised sildenafil AUC 11-fold, and erythromycin raised peak concentration by 160% and AUC by 182% [1]. Tirzepatide is not metabolized by CYP enzymes and has low in vitro potential to inhibit or induce them [2].

Absorption is a separate question from metabolism. Tirzepatide delays gastric emptying, and the delay is largest after the first dose and diminishes over time [2]. The label's own probe was acetaminophen: after a first 5 mg dose, peak acetaminophen concentration fell 55% and peaked an hour later, while at week 6 on 15 mg there was no meaningful effect on peak concentration or time to peak, and total exposure was unchanged [2]. Sildenafil is also affected by food: a high-fat meal delays its peak by about 60 minutes and cuts peak concentration by 29% [1], and its half-life is about 4 hours [1]. Neither label gives data on sildenafil absorption when taken with tirzepatide.

Does the sildenafil dose need to change with Zepbound?

The Viagra label lists specific situations that call for a 25 mg starting dose instead of 50 mg: age over 65, hepatic impairment such as cirrhosis, creatinine clearance below 30 mL/min, treatment with strong CYP3A4 inhibitors (ketoconazole, itraconazole, saquinavir) or erythromycin, and starting sildenafil in a patient who is stable on an alpha-blocker [1]. Tirzepatide is not one of those situations, and no dose change for the pair appears in either label [2][1].

Sildenafil AUC is about 84% higher in healthy men aged 65 or older than in younger men, and the label suggests considering 25 mg as a starting dose in that group [1]. Exposure is also roughly doubled in severe renal impairment and 85% higher in Child-Pugh A or B hepatic impairment, both of which carry the same 25 mg suggestion [1]. Tirzepatide itself needs no dose adjustment for renal or hepatic impairment [2].

The nitrate contraindication is a different thing

The absolute contraindication with sildenafil is nitric oxide donors: organic nitrates or organic nitrites in any form, plus guanylate cyclase stimulators such as riociguat [1]. The label states that after sildenafil has been taken, it is unknown when nitrates can be safely given [1]. In a crossover study, men given sildenafil 25 mg three times daily for 4 days were significantly less tolerant of an intravenous glyceryl trinitrate infusion, judged by a fall in blood pressure greater than 25 mmHg or symptomatic hypotension (p<0.01), and a 500 microgram sublingual glyceryl trinitrate tablet produced a four-fold greater fall in systolic blood pressure [3].

What about sildenafil for pulmonary arterial hypertension (Revatio)?

Revatio is sildenafil 20 mg three times daily for pulmonary arterial hypertension [4][5], while Viagra is labeled for erectile dysfunction. The Viagra label says not to combine Viagra with Revatio or other PDE5 inhibitors, a combination that was not studied and may lower blood pressure further [1]. The same label says erectile dysfunction treatments should not generally be used in men for whom sexual activity is inadvisable because of cardiovascular status, and lists groups with no controlled data, including recent heart attack, stroke or life-threatening arrhythmia, and cardiac failure or unstable angina [1].

Dizziness and low blood pressure on each label

Both labels list dizziness among their adverse reactions: 4% to 5% of Zepbound-treated patients versus 2% on placebo [2], and 3% to 4% of sildenafil-treated men versus 2% on placebo. The Viagra label lists postural hypotension among events in fewer than 2% of trial patients, with a causal relationship uncertain [1].